pattern-detail

About The Webinar

The new Section 232 tariffs on pharmaceuticals raise broader legal, compliance, and supply chain considerations for companies operating in this sector. This webinar will examine what these measures may mean for manufacturers, importers, and downstream market participants. Our speaker will discuss the practical challenges companies may face in assessing exposure, managing compliance risk, and planning for operational disruption, as well as what steps companies can take to respond.


Contact webinarorganizers@strtrade.com if you have issues registering. Please note we do not take American Express.

All attendees will receive a copy of the recording and presentation no later than 2 business days after the conclusion of the webinar. 

Please note webinars are hosted by World Trade Interactive, Inc. Payments for our webinars will appear as World Trade Interactive, Inc. on your statement. 

Veterans and active military: Email webinarorganizers@strtrade.com to receive a discount. Thank you for your service! 

Key Topics

  • Explanation of the new Section 232 tariffs on pharmaceuticals
  • Key compliance and reporting considerations triggered by Section 232 trade actions
  • Compliance considerations for companies navigating heightened trade and enforcement scrutiny

Speaker

Andrea K. Jeglum

Associate
781-559-0140 ajeglum@strtrade.com

ANDREA K. JEGLUM is an associate with Sandler, Travis & Rosenberg, P.A., located in the Boston area. She concentrates her practice on customs compliance matters including tariff classification, country of origin, valuation, trade agreements, foreign-trade zones, and duty reduction programs. She also helps clients meet U.S. requirements concerning trade in biopharma, agro-chemicals, and animal products, including endangered species, as well as export filings and enforcement measures.  

781-559-0140 ajeglum@strtrade.com

Close

Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.